Scarica l'app Stockscreener
502.47
3.12%
-16.19
Dopo l'orario di chiusura:
512.51
10.04
+2.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$518.66
Aprire:
$518.22
Volume 24 ore:
331.05K
Relative Volume:
0.95
Capitalizzazione di mercato:
$11.58B
Reddito:
$958.40M
Utile/perdita netta:
$-288.28M
Rapporto P/E:
-39.06
EPS:
-12.8641
Flusso di cassa netto:
$-193.02M
1 W Prestazione:
-2.75%
1M Prestazione:
-8.12%
6M Prestazione:
+5.59%
1 anno Prestazione:
+64.00%
Intervallo 1D:
$497.23
$522.01
Intervallo di 1 settimana:
$497.23
$524.80
Portata 52W:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Nome
Madrigal Pharmaceuticals Inc
Settore
Industria
Telefono
404-380-9263
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
502.47 | 11.96B | 958.40M | -288.28M | -193.02M | -12.86 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-06 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-28 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-06-28 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Iniziato | BofA Securities | Underperform |
| 2024-03-15 | Aggiornamento | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-02-26 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Reiterato | Oppenheimer | Outperform |
| 2022-12-19 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-19 | Reiterato | Piper Sandler | Overweight |
| 2022-12-19 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-11-24 | Ripresa | Evercore ISI | Outperform |
| 2020-11-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-05 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-01-30 | Iniziato | Canaccord Genuity | Buy |
| 2020-01-09 | Aggiornamento | UBS | Neutral → Buy |
| 2019-11-07 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-06-10 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-12-12 | Iniziato | B. Riley FBR | Neutral |
| 2018-11-19 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Iniziato | Citigroup | Buy |
| 2018-08-06 | Downgrade | Goldman | Buy → Neutral |
| 2018-06-28 | Iniziato | Raymond James | Mkt Perform |
Mostra tutto
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH - MedCity News
Madrigal earnings on deck: Can Rezdiffra sustain blockbuster pace? - Investing.com
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - Pharmaceutical Technology
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead - BioSpace
Madrigal Pharmaceuticals Inc announces exclusive global license for Aro-Pnpla3 from Arrowhead - marketscreener.com
Arrowhead licenses MASH drug candidate to Madrigal for $1B By Investing.com - Investing.com Australia
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline - The Manila Times
After 46% liver fat cut, Madrigal licenses Arrowhead MASH drug - Stock Titan
Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals. - Bitget
3 Biotech Stocks to Watch for Respectable Growth Beyond AI - AOL.com
(MDGL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
MSN Money - MSN
Madrigal upgraded at Cantor on Rezdiffra launch - MSN
MDGL Technical Analysis | Trend, Signals & Chart Patterns | MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) - ChartMill
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $536 - Moomoo
Madrigal Expands Resmetirom Reach With New Post-Transplant MASH Trial - TipRanks
Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo! Finance Canada
Madrigal Pharmaceuticals (MDGL) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
3,876 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Moody Aldrich Partners LLC - MarketBeat
Madrigal to Report Q1 2026 Results May 6, Host Webcast - MyChesCo
Madrigal Pharmaceuticals Reclassifies Board Ahead of 2026 Meeting - TipRanks
Madrigal Pharmaceuticals | 8-K: Current report - Moomoo
Madrigal Pharmaceuticals (NASDAQ: MDGL) reshapes Board classes ahead of 2026 meeting - Stock Titan
Madrigal Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo
[ARS] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Madrigal Pharmaceuticals | DEFA14A: Others - Moomoo
Madrigal Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish (NASDAQ:MDGL) - Seeking Alpha
Madrigal Grants Equity Awards to 12 New Employees - MyChesCo
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead. - BioPharma Dive
Pictet Asset Management Holding SA Sells 9,847 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals gains amid renewed takeover speculation - MSN
Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN
M&T Bank Corp Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 31% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Calamos Advisors LLC Boosts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Here are the most and least likely M&A targets in biotech, according to Truist - MSN
Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge - MSN
Madrigal Pharmaceuticals - The Pharma Letter
Lobbying Update: $380,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):